HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimers disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimers Disease Assessment Scale Cognitive Subscale (ADAS-cog14) relative to placebo. The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimers disease and type 2 diabetes. The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35. These differences were not statistically significant. Consistent with previous studies, azeliragon was generally well-tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups.
We will continue to analyze the data to determine if there are potential benefits or future applications for azeliragon in Alzheimers, dementia or related indications that we or other interested parties may seek to pursue, said Steve Holcombe, chief executive officer, vTv Therapeutics. On behalf of vTv Therapeutics, we would like to extend our most sincere and heartfelt gratitude to study participants, their families, physicians and caregivers for their commitment to this important study despite the challenging circumstances created by the COVID-19 pandemic.
AboutvTv TherapeuticsvTv Therapeutics Inc.is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimers and related dementia, and inflammatory disorders. vTvs development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), genetic mitochondrial diseases, and chronic kidney disease. For more information, please visitwww.vtvtherapeutics.comor follow us on Twitter: @vTvTherapeutics.
Forward-Looking StatementsThis release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading Risk Factors in our Annual Report on Form 10-K and our other filings with theSEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.
Contacts
Investors:
Corey DavisLifeSci AdvisorsCDavis@LifeSciAdvisors.com
or
Media:Glenn SilverLazar FINN Partners646-871-8485gsilver@lazarpartners.com
Source: vTv Therapeutics Inc.
- Global report on diabetes - World Health Organization (WHO) - October 22nd, 2024
- Ultra-processed food may be particularly harmful for people with diabetes, scientists warn - The Independent - October 22nd, 2024
- New drugs may be able to treat multiple problems beyond diabetes - The Straits Times - October 22nd, 2024
- Best Fruits for Diabetes (and What To Avoid) - Health Essentials - October 22nd, 2024
- Cutting Sugar May Reduce Your Diabetes, Stroke, and Depression Risk - Healthline - October 22nd, 2024
- Can Diabetes Care Teams Improve Patient Outcomes and Value? - Medscape - October 22nd, 2024
- Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD - MD Magazine - October 22nd, 2024
- High expression of CNOT6L contributes to the negative development of type 2 diabetes - Nature.com - October 22nd, 2024
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic... - October 22nd, 2024
- Dental teams could detect undiagnosed diabetes in more than one million people with new care pathway - Nature.com - October 22nd, 2024
- Groundbreaking Innovations in Diabetes Care: Highlights from the 2024 Diabetes Technology Meeting - Beyond Type 1 - October 22nd, 2024
- COVID-19 linked to type 2 diabetes onset in children - Medical Xpress - October 22nd, 2024
- The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel... - October 22nd, 2024
- Does microdosing Ozempic work? What experts are saying about the diabetes drug also used for weight loss - Medical Xpress - October 22nd, 2024
- The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024 - Managed Healthcare Executive - October 22nd, 2024
- The overexpression of human amylin in pancreatic cells facilitate the appearance of amylin aggregates in the kidney contributing to diabetic... - October 22nd, 2024
- RNAO releases updated guidelines for diabetic foot ulcer care - Benefits and Pensions Monitor - October 22nd, 2024
- COVID-19 raises the risk of type 2 diabetes in children, study reveals - News-Medical.Net - October 22nd, 2024
- Semaglutide: What impact does it really have on heart health? - Medical News Today - October 22nd, 2024
- Glucose monitors for diabetes have finally been funded but a chronic workforce shortage will limit the benefits - The Conversation - October 22nd, 2024
- Early vs Late Fast Window: Is One More Effective? - Medscape - September 13th, 2024
- Breakthrough T1D Walk to Cure Type 1 Diabetes - KATU - September 13th, 2024
- Foods That May Increase Kids' Risk of Type 1 Diabetes Revealed - Newsweek - September 13th, 2024
- Beds and Herts patients to be re-tested in diabetes results error - BBC.com - September 13th, 2024
- This common habit increases your diabetes risk by 50%; Heres how to fix it - The Economic Times - September 13th, 2024
- Elevated risk of pre-diabetes and diabetes in people with past history of COVID-19 in northeastern Nigeria - BMC Public Health - September 13th, 2024
- Study links bananas, oats and yoghurt to greater diabetes risk in susceptible children - The Guardian - September 13th, 2024
- Could the Norton research teams studying diabetes and Alzheimer's come up with a cure? - Courier Journal - September 13th, 2024
- Weight loss, better beta-cell function tied to long-term glycemic control with tirzepatide - Healio - September 13th, 2024
- Study finds weekly insulin injections as effective for diabetes as daily shots - UPI News - September 13th, 2024
- Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Heres what the science says - The Conversation - September 13th, 2024
- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes - PR Newswire - September 13th, 2024
- Dining with Diabetes workshops offered - The Courier-Express - September 13th, 2024
- Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing - News-Medical.Net - September 13th, 2024
- The menopause can increase your likelihood of developing heart disease, type 2 diabetes and hypertension but exercise can help lower risk - The... - September 13th, 2024
- Artificial pancreas shows promise in people with type 1 diabetes on kidney dialysis - MSN - September 13th, 2024
- How an Indian executive battled flesh-eating disease and diabetes, and won - South China Morning Post - September 13th, 2024
- India brings early Diabetic Retinopathy detection to the last mile with Artificial Intelligence - PR Newswire - September 13th, 2024
- Why this diabetes drug may be the answer to NASA search for radiation protection - Texas Public Radio - September 13th, 2024
- The National Association of Chain Drug Stores and the American Diabetes Association Promote Nutrition Security and its Role in Preventing and Managing... - September 13th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023
- Diabetes and Hearing Loss with Concept by Iowa Hearing | Paid Content - Local 5 - weareiowa.com - May 9th, 2023
- COUNTY COLUMN: Learn to Live well with diabetes at The Well - Norman Transcript - May 1st, 2023
- Want to Cut Type 2 Diabetes Risk? This High-fat Food Can Be the Answer, According to New Study - Revyuh - May 1st, 2023
- Diabetes: What It Is, Causes, Symptoms, Treatment & Types - March 13th, 2023
- A number of healthtech startups claim they can reverse Type 2 diabetes. But caveats apply, caution doctors - Economic Times - March 13th, 2023
- Tampa doctor who lost brother to diabetes calls insulin price cut a 'game changer' - ABC Action News Tampa Bay - March 5th, 2023
- New study suggest people previously infected with COVID-19 could have increased risk for diabetes - CBS Los Angeles - February 16th, 2023
- Diabetes Symptoms, Causes, & Treatment | ADA - October 15th, 2022
- A nutritionist with type 1 diabetes shares the top 5 'food swaps' she eats to manage her blood sugar - CNBC - October 15th, 2022
- Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today - October 15th, 2022
- Milton teen involved in launch of diabetes support program - Milton Daily Standard - October 15th, 2022
- Providers Now Have Free Access to Latest Diabetes Technology in One Place - PR Newswire - October 15th, 2022
- 5 Modifiable Factors in Women with History of Gestational Diabetes Mellitus That Can Reduce the Risk of T2D - Pharmacy Times - October 15th, 2022
- BCMH the stoy of Diabetes and Determination - 921News - October 15th, 2022
- Can skipping a meal lead to diabetes and fat around abdomen? - The Indian Express - October 15th, 2022
- Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 -... - October 15th, 2022
- Diabetes: Symptoms, risks, and prevention - Wilmington News Journal, OH - July 17th, 2022
- Diabetes symptoms: The sign of nerve damage that often strikes at night - severe - Express - July 17th, 2022
- Local Teen Brings Smiles and Health Kits to Kids with Diabetes - River Journal Staff - July 17th, 2022
- Type 3 diabetes: symptoms, causes and treatments - Livescience.com - July 17th, 2022
- Diabetes Travel Essentials and Tips for the Approximately 21 Million Americans that Must Manage Their Diabetes While on Vacation - PR Newswire - July 17th, 2022
- A type of 'step therapy' is an effective strategy for diabetic eye disease - National Institutes of Health (.gov) - July 17th, 2022
- Diabetes education: one in five search results for diabetes lack reliable information - Open Access Government - July 17th, 2022
- Arch City Kids Theater Troupe Fights Type 1 Diabetes With Its Annual Revue - Broadway World - July 17th, 2022
- Nutrigenomics Testing Industry Forecast to 2027 - Insights Into Obesity, Diabetes, Cancer, and Cardiovascular Disease Applications -... - July 17th, 2022
- Harvard Scientists Have Developed a Revolutionary New Treatment for Diabetes - SciTechDaily - June 16th, 2022
- Do Viruses and Coxsackievirus Cause Type 1 Diabetes? - Healthline - June 16th, 2022
- Diabetes Week: Types 1 and 2 symptoms, causes and prevention - Yahoo Entertainment - June 16th, 2022
- Diabetes And Sex: Have Safe Sex While Managing Diabetes - MadameNoire - June 16th, 2022
- Diabetes Devices Market to Expand at the CAGR of 6.4% from 2019 to 2027, Increase in Prevalence of Diabetes Expected to Drive Global Market - BioSpace - June 16th, 2022
- Anemia and Diabetes: What You Should Know - Healthline - June 16th, 2022
- Patient Knowledge of Diabetes and CKD in an Inner-City Population - DocWire News - June 16th, 2022
- ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM - PR Newswire - June 16th, 2022
- Understanding the Link between Diabetes Care and Sickle Cell Disease | NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases... - June 16th, 2022
- Child type 2 diabetes referrals in England and Wales jump 50% amid obesity crisis - The Guardian - June 16th, 2022